NOVARTIS PHARMS CORP
FDA approval date:
ADAKVEO is a selectin blocker indicated to reduce the frequency of
vasoocclusive crises in adults and pediatric patients aged 16 years and older
with sickle cell disease
Mechanism of Action:
Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with
its ligands including P-selectin glycoprotein ligand 1.
Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells,
platelets, red blood cells, and leukocytes.
Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.
Most common adverse reactions (incidence > 10%) are nausea, arthralgia,
back pain, and pyrexia.